Dados B3 › ODER4 × JBSS3
ODER4 × JBSS3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | ODER4 | JBSS3 | year |
|---|---|---|---|
| ROE | 0.0% | 24.8% | 2025 |
| ROIC | 10.6% | 14.4% | 2025 |
| ROA | 7.0% | 5.0% | 2025 |
| Gross margin | 28.8% | 13.1% | 2025 |
| EBIT margin | 13.5% | 4.9% | 2025 |
| Net margin | 9.1% | 2.6% | 2025 |
| Net debt/EBITDA | 2.55x | 3.94x | 2018 |
| Current ratio | 3.30x | 1.60x | 2025 |
| Revenue growth (1y) | 13.0% | 15.3% | 2025 |
| Revenue growth (5y CAGR) | 7.5%! | 12.2% | 2025 |
| Piotroski F-Score | 8/9 | 7/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | ODER4 | JBSS3 | year |
|---|---|---|---|
| P/E | — | 9.40x | None × 2024 |
| P/B | — | 2.02x | None × 2024 |
| EV/EBITDA | — | 4.90x | None × 2024 |
| FCF yield | — | 17.1% | None × 2024 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 15:47 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.